186 related articles for article (PubMed ID: 26089540)
1. Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial.
Felix AS; Brinton LA; McMeekin DS; Creasman WT; Mutch D; Cohn DE; Walker JL; Moore RG; Downs LS; Soslow RA; Zaino R; Sherman ME
J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26089540
[TBL] [Abstract][Full Text] [Related]
2. Prior Tubal Ligation Might Influence Metastatic Spread of Nonendometrioid Endometrial Carcinoma.
Li M; Li M; Zhao L; Wang Z; Wang Y; Shen D; Wang J; Wei L
Int J Gynecol Cancer; 2016 Jul; 26(6):1092-7. PubMed ID: 27104940
[TBL] [Abstract][Full Text] [Related]
3. Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial.
Felix AS; Scott McMeekin D; Mutch D; Walker JL; Creasman WT; Cohn DE; Ali S; Moore RG; Downs LS; Ioffe OB; Park KJ; Sherman ME; Brinton LA
Gynecol Oncol; 2015 Oct; 139(1):70-6. PubMed ID: 26341710
[TBL] [Abstract][Full Text] [Related]
4. Detection of endometrial cancer cells in the fallopian tube lumen is associated with adverse prognostic factors and reduced survival.
Felix AS; Sinnott JA; Vetter MH; Rhoades J; Cohn DE; Backes FJ; Sherman ME; Suarez AA
Gynecol Oncol; 2018 Jul; 150(1):38-43. PubMed ID: 29754740
[TBL] [Abstract][Full Text] [Related]
5. Tubal ligation could reduce mortality in endometrial cancer.
Gruber K
Lancet Oncol; 2015 Aug; 16(8):e380. PubMed ID: 26118964
[No Abstract] [Full Text] [Related]
6. Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study.
Felix AS; Cohn DE; Brasky TM; Zaino R; Park K; Mutch DG; Creasman WT; Thaker PH; Walker JL; Moore RG; Lele SB; Guntupalli SR; Downs LS; Nagel CI; Boggess JF; Pearl ML; Ioffe OB; Randall ME; Brinton LA
Am J Obstet Gynecol; 2018 Nov; 219(5):459.e1-459.e11. PubMed ID: 30096321
[TBL] [Abstract][Full Text] [Related]
7. Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma.
Ayeni TA; Bakkum-Gamez JN; Mariani A; McGree ME; Weaver AL; AlHilli MM; Martin JR; Keeney GL; Dowdy SC; Podratz KC
Gynecol Oncol; 2013 Jan; 128(1):71-76. PubMed ID: 23127971
[TBL] [Abstract][Full Text] [Related]
8. Transtubal spread of endometrial carcinoma: correlation of intra-luminal tumour cells with tumour grade, peritoneal fluid cytology, and extra-uterine metastasis.
Stewart CJ; Doherty DA; Havlat M; Koay MH; Leung YC; Naran A; O'Brien D; Ruba S; Salfinger S; Tan J
Pathology; 2013 Jun; 45(4):382-7. PubMed ID: 23635815
[TBL] [Abstract][Full Text] [Related]
9. Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.
Felix AS; Brasky TM; Cohn DE; Mutch DG; Creasman WT; Thaker PH; Walker JL; Moore RG; Lele SB; Guntupalli SR; Downs LS; Nagel C; Boggess JF; Pearl ML; Ioffe OB; Deng W; Miller DS; Brinton LA
Int J Cancer; 2018 Mar; 142(6):1102-1115. PubMed ID: 29063589
[TBL] [Abstract][Full Text] [Related]
10. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
Trovik J; Wik E; Werner HM; Krakstad C; Helland H; Vandenput I; Njolstad TS; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; ; Amant F; Akslen LA; Salvesen HB
Eur J Cancer; 2013 Nov; 49(16):3431-41. PubMed ID: 23932335
[TBL] [Abstract][Full Text] [Related]
11. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
Benedetti Panici P; Basile S; Maneschi F; Alberto Lissoni A; Signorelli M; Scambia G; Angioli R; Tateo S; Mangili G; Katsaros D; Garozzo G; Campagnutta E; Donadello N; Greggi S; Melpignano M; Raspagliesi F; Ragni N; Cormio G; Grassi R; Franchi M; Giannarelli D; Fossati R; Torri V; Amoroso M; Crocè C; Mangioni C
J Natl Cancer Inst; 2008 Dec; 100(23):1707-16. PubMed ID: 19033573
[TBL] [Abstract][Full Text] [Related]
12. Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence.
Brasky TM; Felix AS; Cohn DE; McMeekin DS; Mutch DG; Creasman WT; Thaker PH; Walker JL; Moore RG; Lele SB; Guntupalli SR; Downs LS; Nagel CI; Boggess JF; Pearl ML; Ioffe OB; Park KJ; Ali S; Brinton LA
J Natl Cancer Inst; 2017 Mar; 109(3):1-10. PubMed ID: 28376204
[TBL] [Abstract][Full Text] [Related]
13. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
[TBL] [Abstract][Full Text] [Related]
14. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.
Brinton LA; Felix AS; McMeekin DS; Creasman WT; Sherman ME; Mutch D; Cohn DE; Walker JL; Moore RG; Downs LS; Soslow RA; Zaino R
Gynecol Oncol; 2013 May; 129(2):277-84. PubMed ID: 23485770
[TBL] [Abstract][Full Text] [Related]
15. Transtubal transport of carcinoma cells into the peritoneal cavity after saline infusion via transcervical route in patients with endometrial carcinoma.
Bese T; Demirkiran F; Guralp O; Sanioglu C; Arvas M
Int J Gynecol Cancer; 2009 May; 19(4):682-5. PubMed ID: 19509571
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of aortic lymph node metastasis in endometrial cancer: Potential implications for selective aortic lymph node assessment.
Cosgrove CM; Cohn DE; Rhoades J; Felix AS
Gynecol Oncol; 2019 Jun; 153(3):505-510. PubMed ID: 30935714
[TBL] [Abstract][Full Text] [Related]
17. Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.
Winder AD; Maniar KP; Wei JJ; Liu D; Scholtens DM; Lurain JR; Schink JC; Buttin BM; Filiaci VL; Lankes HA; Ramirez NC; Park K; Singh M; Lieberman RW; Mannel RS; Powell MA; Backes FJ; Mathews CA; Pearl ML; Secord AA; Peace DJ; Mutch DG; Creasman WT; Kim JJ
Cancer; 2017 Apr; 123(7):1144-1155. PubMed ID: 27926776
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Patients With Surgically and Pathologically Staged IIIA-IVB Pure Endometrioid-type Endometrial Cancer: A Taiwanese Gynecology Oncology Group (TGOG-2005) Retrospective Cohort Study (A STROBE-Compliant Article).
Chen JR; Chang TC; Fu HC; Lau HY; Chen IH; Ke YM; Liang YL; Chiang AJ; Huang CY; Chen YC; Hong MK; Wang YC; Huang KF; Hsiao SM; Wang PH
Medicine (Baltimore); 2016 Apr; 95(15):e3330. PubMed ID: 27082583
[TBL] [Abstract][Full Text] [Related]
19. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey.
Lajer H; Elnegaard S; Christensen RD; Ortoft G; Schledermann DE; Mogensen O
Acta Obstet Gynecol Scand; 2012 Aug; 91(8):976-82. PubMed ID: 22548255
[TBL] [Abstract][Full Text] [Related]
20. Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer.
Matsuo K; Nusbaum DJ; Matsuzaki S; Chang EJ; Roman LD; Wright JD; Harter P; Klar M
Gynecol Oncol; 2020 Oct; 159(1):43-51. PubMed ID: 32690393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
